Litigation Details for Silvergate Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2019)
✉ Email this page to a colleague
Silvergate Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-04-11 |
| Court | District Court, D. Delaware | Date Terminated | 2021-06-29 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | 10,039,745; 10,154,987; 6,211,244; 6,316,460; 9,375,405; 9,669,008; 9,808,442 | ||
| Attorneys | Talin Gordnia | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Silvergate Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC
Biologic Drugs cited in Silvergate Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Silvergate Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-07-22 | 109 | Notice of Service | Buckton on Infringement of U.S. Patent 9,669,008; 9,808,442; 10,039,745; and 10,154,987; and (2) Opening…John D. Mahan, Jr., M.D. on Infringement of U.S. Patent 9,808,442 and 10,154,987 filed by Silvergate Pharmaceuticals… 11 April 2019 1:19-cv-00678 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-08-21 | 111 | Notice of Service | Graham Buckton on Validity of U.S. Patent 9,669,008; 9,808,442; 10,039,745; and 10,154,987; (2) Expert Report… 11 April 2019 1:19-cv-00678 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-10-02 | 114 | Notice of Service | Buckton on Infringement of U.S. Patent 9,669,008; 9,808,442; 10,039,745; and 10,154,987 filed by Silvergate… 11 April 2019 1:19-cv-00678 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-10-29 | 117 | Redacted Document | the ’745 Patent U.S. Patent No. 10,039,745 the ’987 Patent U.S. Patent No. 10,154,987 Original…Application the ’008 Patent U.S. Patent No. 9,669,008 the ’442 Patent U.S. Patent No. 9,808,442 the…the ’868 patent U.S. Patent No. 10,772,868 New Patents The ’482 and ’868 patents, collectively…infringement of the ’008 Patent, the ’442 Patent, the ’745 Patent, and the ’987 Patent (collectively, the …Original Patents The ’008, ’442, ’745, and ’987 patents, collectively the ’482 patent U.S. Patent | External link to document |
| 2020-10-30 | 119 | 2 through 24 as obvious “over Van Wagenen (US 6,211,244 B1) as evidenced by Kajiyama et al. (US 6,656,492…consolidated patent infringement action arising under the Drug Price Competition and Patent Term Restoration…Hatch-Waxman Act. United States Patent No. 9,375,405 (the “’405 patent”) is assigned to Plaintiff Amgen…BACKGROUND A. The ’405 Patent The ’405 patent, entitled “Rapid Dissolution Formulation… was issued by the United States Patent and Trademark Office (“Patent Office”) on June 28, 2016. (D. | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
